Abstract
Pharmacotherapeutic response testing identified CFTR Ser1159Pro as responsive to cystic fibrosis modulator therapy
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. McCarthy has nothing to disclose.
Conflict of interest: Dr. Brewington has nothing to disclose.
Conflict of interest: Ms. Harkness has nothing to disclose.
Conflict of interest: Dr. Clancy has nothing to disclose.
Conflict of interest: Dr. Trapnell has nothing to disclose.
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©ERS 2018